Pharmaceutical giant AstraZeneca has warned earnings will come in at the lower end of expectations after it took a $381.5m hit from failed drug tests.
The company has stopped development of its ovarian cancer treatment olaparib and also said its antidepressant compound TC-5214 had not met targets.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
These impairments would push down the company's core earnings per share by around $0.21 in the fourth quarter, it said.
This meant that while full year core EPS would remain in the predicted range of $7.20 to $7.40, earnings were likely to be in the lower half of this scale.
The company is taking an impairment of $285m pre-tax charge due to the failure of olaparib, with a further $96.5m hit based on the lower probability of success for the remaining TC-5214 studies.
Shares in AstraZeneca fell 2% in early trading following the announcement.
-
Steve Webb: The triple lock is there to do a job. I’m not embarrassed or ashamed of itThe triple lock means 13 million pensioners will now get an above-inflation state pension boost in April. While the rising cost of the policy has stirred controversy, Steve Webb, who served as pensions minister when it was introduced, argues the triple lock is vital and should stay. Webb speaks to Kalpana Fitzpatrick on the new episode of MoneyWeek Talks – out now.
-
How retirement pots risk running out 11 years early if inflation remains highPension savers could find their retirement income may not last as long as they anticipated over fears that inflation may not slow down
